Nicox Earnings Inline, Revenue misses In Q2
- Investing.com
- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Nicox SA (ALCOX)
Assess today's live Nicox SA (ALCOX) share price, performance and insights using our live Paris: ALCOX stock exchange data.
Analyse the historical data and Nicox SA share price performance charts on this page. Our technical summary section provides analysis on Nicox share price buy/sell indicators using real-time data (or discuss the Nicox (ALCOX) stock price today with other investors in the Nicox EPA share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current EPA ALCOX share price (ISIN: FR0013018124) to enhance your trading decisions with our free investment tools and resources.
What Is the Nicox SA Share Price Today?
The Nicox share price today is 0.300.
What Is the Stock Symbol for Nicox SA
The stock symbol (or 'ticker') for Nicox SA is "ALCOX."
What Stock Exchange Does Nicox SA Trade On?
Nicox SA is listed and trades on the Paris stock exchange.
Is Nicox SA a Good Stock to Buy?
Determining whether Nicox SA—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Analyse the historical data and Nicox SA share price performance charts on this page. Our technical summary section provides analysis on Nicox share price buy/sell indicators using real-time data (or discuss the Nicox (ALCOX) stock price today with other investors in the Nicox EPA share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current EPA ALCOX share price (ISIN: FR0013018124) to enhance your trading decisions with our free investment tools and resources.
What Is the Nicox SA Share Price Today?
The Nicox share price today is 0.300.
What Is the Stock Symbol for Nicox SA
The stock symbol (or 'ticker') for Nicox SA is "ALCOX."
What Stock Exchange Does Nicox SA Trade On?
Nicox SA is listed and trades on the Paris stock exchange.
Is Nicox SA a Good Stock to Buy?
Determining whether Nicox SA—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Paris
Currency in EUR
0.300
-0.002(-0.66%)
Real-time Data
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.297
0.304
52 wk Range
0.140
0.492
ALCOX Scorecard
Full Analysis
Suffers from weak gross profit margins
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.2970.304
52 wk Range
0.1400.492
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ALCOX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceFair Price
Upside
Price Target
1.000
Upside
+233.33%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts do not anticipate the company will be profitable this year
- Nicox Earnings Inline, Revenue misses In Q2
- Investing.com
Nicox Company Profile
Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial. Nicox S.A. is developing NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals that is in Phase 2b clinical trial for the treatment of dry eye disease; and NCX 1728, an NO-donating Phosphodiesterase-5 inhibitor, which is in preclinical evaluation. In addition, the company offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular related associated with allergic conjunctivitis. Nicox S.A. was founded in 1996 and is headquartered in Valbonne, France.
Compare ALCOX to Peers and Sector
Metrics to compare | ALCOX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipALCOXPeersSector | |
|---|---|---|---|---|
P/E Ratio | - | −1.0x | −0.6x | |
PEG Ratio | - | −0.01 | 0.00 | |
Price/Book | - | 0.3x | 2.6x | |
Price / LTM Sales | - | 3.8x | 3.1x | |
Upside (Analyst Target) | 253.4% | 198.0% | 54.8% | |
Fair Value Upside | Unlock | 19.2% | 7.9% | Unlock |
Analyst Ratings
1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 1.000
(+233.33% Upside)
Earnings
Latest Release
Oct 17, 2024
EPS / Forecast
-0.06 / -0.06
Revenue / Forecast
1.20M / 1.20M
People Also Watch
FAQ
What Is the Nicox (ALCOX) Stock Price Today?
The Nicox stock price today is 0.30
What Stock Exchange Does Nicox Trade On?
Nicox is listed and trades on the Paris stock exchange.
What Is the Stock Symbol for Nicox?
The stock symbol for Nicox is "ALCOX."
What Is the Nicox Market Cap?
As of today, Nicox market cap is 20.57M.
What Is the Next Nicox Earnings Date?
Nicox will release its next earnings report on 26 Feb 2025.
From a Technical Analysis Perspective, Is ALCOX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.